Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $32.2152W HIGH $170.87
Volume
1.79 M
Value Traded
114.74 M
Short % Float
20.83%
Days to Cover
8.7
+2.54%Week
+2.98%1 Month
-15.61%3 Month
+65.92%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.96 B
EPS (TTM)
-3.57
P/E Ratio
-
Ent. Value
1.93 B
Total Shares
29.82 M
Float Shares
28.90 M
Insiders
3.10%
Institutions
106.40%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
WGS Catalyst Timeline
Dated clinical, regulatory and corporate events for GeneDx Holdings Corp. Class A Common Stock
Catalyst Timeline
Dated clinical, regulatory & corporate events for GeneDx Holdings Corp. Class A Common Stock
15Total events
0Upcoming
0Tier-1 (high impact)
2025 to 2026Coverage
Event history 12
●R&D DayPresentation
GeneDx management fireside chat at Wells Fargo 21st Annual Healthcare Conference
●R&D DayPresentation
GeneDx management fireside chat at Canaccord Genuity 46th Annual Growth Conference
▲Debt Royalty FinancingCorporate
Amended and restated loan agreement with Blackstone, adding $50M term loan facility
●Equity OfferingCorporate
Blackstone affiliate to purchase ~$5.0M of Class A common stock at $61.00 per share
▲Reimbursement / PricingPost-Market
Mississippi Medicaid coverage for exome and genome sequencing effective
▲Reimbursement / PricingPost-Market
California Medicaid coverage for genome sequencing effective
Past FDA Catalysts and PDUFA Decisions
How WGS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
GeneDx Holdings Corp. Class A is a services and tools company (CRO, lab tools or healthcare services). The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every WGS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Fuchs ThomasDirector | Option | 1,146 1,146 held | $0.00 | 09/17/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in WGS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Casdin Capital, LLC | 12.7 % (-13 %) | 254.50 M | 3.71 M | 23.28% ( 700.00 K) |
Ownership Trends
WGS Short Interest
Shares sold short, counted twice a month.
20.83%
Short % of Float
of tradable shares sold short
6.0M
Shares Sold Short
+7.0% vs prior count
8.7 High
Days to Cover
trading days of normal volume to buy every short share back
689.8K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-13 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How WGS ranks across every disease it competes in
Competitive Position is a premium feature
See how WGS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialWGS News
-WGS
Nov 9, 2026▲ +5.4%today
GeneDx Reports Third Quarter 2026 Financial Results
GeneDx reported third quarter 2026 revenue of $123.1 million, a 5% increase year-over-year. Adjusted net income rose to $8.6 million, while adjusted gross margin expanded to 72%. The company reiterated its full-year revenue guidance of $475 to $490 million, reflecting confidence in continued growth despite a GAAP net loss of $12.3 million.
Read more →-WGS
Oct 23, 2026▲ +9.1%on this news· ran to +26% by day 3
GeneDx to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026
GeneDx announced it will report its third quarter 2026 financial results on November 9, 2026. The company will host a conference call at 4:30 p.m. Eastern Time to discuss these results. GeneDx is recognized for its leadership in rare disease diagnosis and has developed the largest rare disease genomic dataset.
Read more →-WGS
Oct 20, 2026GeneDx Expands Diagnostic Leadership with Long-Read Genome Sequencing, Advancing Rare Disease Diagnosis
GeneDx has announced the expansion of its diagnostic portfolio with long-read whole genome sequencing (lrWGS), aimed at improving the diagnosis of rare diseases. This innovative approach will allow for the identification of complex genetic variations that traditional sequencing methods may miss. The initiative is set to enhance patient care by providing clearer insights and reducing the time to diagnosis.
Read more →-WGS
Oct 19, 2026GeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026
GeneDx has made significant strides in genomic medicine, presenting 27 abstracts at the ASHG 2026 Annual Meeting. The research emphasizes the importance of exome and genome sequencing as standard care for various conditions, including rare diseases and autism. Key highlights include the use of AI for genomic interpretation and the expansion of equitable newborn screening.
Read more →-WGS
Oct 7, 2026GeneDx Presents New Evidence Advancing Genomic Newborn Screening at ICoNS 2026
GeneDx has presented new evidence that supports the advancement of genomic newborn screening at the ICoNS 2026 conference. This development highlights the company's commitment to enhancing healthcare through innovative genomic solutions. The findings could lead to significant improvements in newborn screening practices.
Read more →-WGS
Oct 2, 2026GeneDx Introduces Easy Order at AAP 2026 to Simplify Genomic Testing in Everyday Pediatric Care
GeneDx has launched Easy Order at the AAP 2026 conference, aimed at simplifying genomic testing in pediatric care. This initiative is expected to enhance accessibility and streamline the process for healthcare providers. The introduction of this tool could lead to improved patient outcomes in everyday pediatric settings.
Read more →-WGS
Sep 9, 2026GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C
GeneDx and Beren Therapeutics have launched NPC GenomeComplete, a new initiative aimed at improving the diagnosis of Niemann-Pick Disease Type C. This collaboration seeks to enhance diagnostic capabilities for this rare genetic disorder. The launch represents a significant step forward in addressing the diagnostic challenges associated with Niemann-Pick Disease Type C.
Read more →-WGS
Sep 1, 2026GeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 Honoree
Katherine Stueland, the CEO of GeneDx, has been honored as a 2026 Fierce 50 honoree for her efforts in promoting health equity. This recognition underscores her leadership and the company's dedication to addressing health disparities. The award reflects a growing emphasis on equitable healthcare solutions.
Read more →-WGS
Aug 24, 2026GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children’s
GeneDx and Seattle Children's have announced a transformative study demonstrating that hospital-wide rapid genomic sequencing can significantly accelerate accurate diagnoses for children. This initiative aims to enhance access to genetic information, providing families with timely answers regarding their children's health. The study underscores the potential of genomic sequencing in pediatric care.
Read more →-WGS
Aug 11, 2026GeneDx Launches New Online Offering for Families to Improve Accessibility of Exome Testing for Children with Global Developmental Delay, Intellectual Disability and Epilepsy
GeneDx has introduced a new online service designed to enhance accessibility to exome testing for children facing global developmental delays, intellectual disabilities, and epilepsy. This initiative aims to provide families with quicker access to essential testing, potentially leading to faster diagnoses and interventions. The launch reflects GeneDx's commitment to improving healthcare access for affected families.
Read more →-WGS
Aug 6, 2026▲ +10.8%on this newsshared move
GeneDx to Participate in Upcoming Investor Conferences
GeneDx has announced its participation in upcoming investor conferences hosted by Canaccord Genuity and Wells Fargo. This engagement reflects the company's strategy to connect with investors and enhance its market presence. Management's involvement suggests a proactive approach to investor relations.
Read more →-WGS
Aug 3, 2026GeneDx Reports Second Quarter 2026 Financial Results
GeneDx has announced its financial and operational results for the second quarter of 2026. The report highlights the company's ongoing activities and performance metrics. As a publicly traded entity on Nasdaq, GeneDx's results are of interest to investors and stakeholders in the biopharma sector.
Read more →-WGS
Jul 16, 2026GeneDx to Report Second Quarter 2026 Financial Results on Monday, August 3, 2026
GeneDx has announced that it will release its financial results for the second quarter of 2026 after the market closes on August 3, 2026. This report is expected to provide insights into the company's performance during this period. The announcement reflects GeneDx's commitment to transparency with its stakeholders.
Read more →-WGS
Jun 16, 2026GeneDx Names Mark Gardner President to Lead Its Next Phase of Scale and Growth Former Quest Diagnostics leader joins to fuel operational and commercial execution
GeneDx has appointed Mark Gardner as President, effective June 15, 2026, to enhance its commercial and operational execution. Gardner, who previously held senior roles at Quest Diagnostics and OmniSeq, brings significant industry experience. CEO Katherine Stueland emphasized the importance of execution as the company enters a growth phase. GeneDx aims to leverage its expansive genomic dataset to advance precision medicine and improve health outcomes in rare diseases.
Read more →-WGS
May 26, 2026GeneDx to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
GeneDx is set to participate in the Goldman Sachs 47th Annual Global Healthcare Conference. This event is significant for stakeholders in the healthcare sector, providing a platform for discussions and networking. Further details regarding the company's agenda or focus during the conference are not provided.
Read more →-WGS
May 4, 2026GeneDx Reports First Quarter 2026 Financial Results and Updates Full-Year Outlook
GeneDx Holdings Corp. reported its first quarter 2026 results, revealing a revenue of $102.3 million with substantial growth in both exome and genome testing. The company experienced a 34% year-over-year increase in testing volume and has adjusted its 2026 revenue guidance to a range of $475 to $490 million. Despite the positive revenue growth, GeneDx reported an adjusted net loss of $8.2 million and a total operating expense that accounted for 76% of its revenue, suggesting financial challenges ahead. The CEO remained optimistic about future growth and profitability as the company navigates the evolving market for genomic services.
Read more →-WGS
Apr 13, 2026GeneDx to Report First Quarter 2026 Financial Results on Monday, May 4, 2026
GeneDx is set to report its financial results for the first quarter of 2026 on May 4, 2026. This announcement provides stakeholders with an upcoming date to anticipate the company's performance metrics. Further details regarding the financial results are expected to be disclosed during this report.
Read more →-WGS
Mar 9, 2026▲ +7.3%on this news
GeneDx to Present 18 Abstracts at ACMG 2026, Showcasing the Scale of GeneDx Infinity™ and Real-World Genomic Leadership
GeneDx announced its participation at the 2026 ACMG Annual Meeting, where it will present 18 abstracts, including platform presentations and poster talks. The research emphasizes advancements in genomic testing, AI-supported interpretation, and the impact of early diagnoses. GeneDx Infinity™, its comprehensive genomic dataset, plays a crucial role in these innovations.
Read more →-WGS
Feb 26, 2026GeneDx to Participate in Upcoming March 2026 Investor Conferences
GeneDx will participate in two upcoming investor conferences in March 2026. The events include a fireside chat on March 2 and a presentation on March 11, both of which will be available via live and archived webcasts. This participation highlights GeneDx's commitment to engaging with investors and showcasing its advancements in genomic diagnostics.
Read more →-WGS
Feb 23, 2026▲ +6.1%on this newsshared move
INSERTING and REPLACING GeneDx Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms Guidance for Full Year 2026
GeneDx Holdings Corp. reported its financial results for Q4 and full year 2025, showcasing strong performance and reaffirming guidance for 2026. The company emphasizes its unique position in the genomic diagnosis market and plans to expand into underpenetrated markets. CEO Katherine Stueland highlighted the company's growth potential and the advantages of their GeneDx Infinity platform.
Read more →About GeneDx Holdings Corp. Class A Common Stock
Headquarters333 LUDLOW STREET, STAMFORD, CT, 06902
BIOPHARMAWATCH ELITE PLUS
Trade the next WGS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime